Published on : Oct 18, 2018
Albany, New York, October 18, 2018: Rheumatoid arthritis is a chronic disease and a long-term auto-immune disorder that primary affects the joints. Janus kinase (JAK) inhibitors are a type of medication, which function by inhibiting the activity of Janus kinase which is a family of enzymes being one or more in number. They are being used in the treatment of rheumatoid arthritis and are said to contribute to the therapeutic landscape meaningfully. Small-molecule JAK inhibitors are proposed to provide a significant alternative to biological therapies for treating inflammatory diseases such as rheumatoid arthritis.
A new business intelligence report titled, “KOL Perspectives: Cardiovascular safety profile of JAK inhibitors in Rheumatoid Arthritis” is added to the expanding repository of Market Research Hub (MRH) examines recent developments and studies the safety concerns that are associated to the use of JAK inhibitors used in treating rheumatoid arthritis.
Recent Study Showcasing the Comparison between JAK Inhibitors and DMARDs with Regards to Cardiovascular Risks
The cardiovascular safety concerns are gaining major attention owing to cases where patients with rheumatoid arthritis suffer from cardiovascular risks. Owing to the metabolic changes by inflammatory cytokines are observed in body composition, insulin sensitivity, and lipid profile of these patients, leading to increased cardiovascular risk. However, disease-modifying anti-rheumatic drugs (DMARDs) showcase beneficial effects on the metabolic changes thereby beneficial in cardiovascular outcomes. Recent data provides a comparative cardiovascular safety between JAK inhibitors and DMARDs. Although DMARDs lowers cardiovascular risks, the safety signals could differ with DMARD treatment despite similar efficacy of the drug.
The in-depth analysis provided in the research report significantly highlights the safety profile of the JAK inhibitors when they are used in the treatment of rheumatoid arthritis. The report includes a KOL insight briefing that focus on the KOL opinions of the safety of JAK inhibitors. A collective analysis of the four JAK inhibitors including Baricitinib, Tofacitinib, Filgotinib, and Upadacitinib in terms of their safety profile regarding cardiovascular signals, included in the report helps in understanding the holistic safety profile of JAK inhibitors.
KOLs highlighted that there was a cardiovascular signal with baricitinib, although many flagged this as not being a concern. Furthermore, they stated a positive opinion about tofacitinib with respect to its cardiovascular profile while many others showcased the need for a safety data. With this comprehensive examination included in the report, the report majorly focuses on providing a deeper understanding of which inhibitors could be an effective measure in tackling rheumatoid arthritis.
With the help of both quantitative and qualitative data and insights and opinions of rheumatoid arthritis Key Opinion Leaders (KOLs), the report is an effective business tool to evaluate the safety profile of the much promised JAK inhibitors. The qualitative insights by healthcare analyst and meaningful recommendations further help in examining the risk associated with JAK inhibitors, thereby helping to prepare in the mitigation with new developments. KOL insights play a significant role when it comes to assessing the cardiovascular safety profile of JAK inhibitors. These insights help in improving how rheumatoid arthritis is treated.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1918130
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org